TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7915235

Group type: EXPERIMENTAL
Intervention: Suriclone (0.4 mg) + Chlorpromazine (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg) + Chlorpromazine (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Suriclone (0.4 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3173922

Group type: EXPERIMENTAL
Intervention: Chorionic villi sampling
Number of subjects: 61

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 61
Study: 29294635

Group type: EXPERIMENTAL
Intervention: Childhood maltreatment (emotional, sexual, multiple abuse experiences)
Number of subjects: 2980

Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 2980

Group type: EXPERIMENTAL
Intervention: Experiencing childhood sexual abuse
Number of subjects: 2980

Group type: EXPERIMENTAL
Intervention: Experiencing multiple types of abuse
Number of subjects: 2980
Study: 29447342

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR)
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Myocardial Perfusion Scintigraphy (MPS)
Number of subjects: 1675
Study: 28594757

Group type: EXPERIMENTAL
Intervention: Lidocaine‐prilocaine cream
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 54
Study: 26290646

Group type: EXPERIMENTAL
Intervention: 0.025-inch GW
Number of subjects: 269

Group type: COMPARATOR
Intervention: 0.035-inch GW
Number of subjects: 269
Study: 24100322

Group type: EXPERIMENTAL
Intervention: Optimized phases for a small number of strong reflections prior to density modification; method involves using the centroid phase as a starting point.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New method for phase improvement in macromolecular crystallography; involves a genetic algorithm optimizing the quality of phases using skewness of the density map as a target function.
Number of subjects: 0
Study: 21765365

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV) based ART
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nevirapine (NVP) based ART
Number of subjects: 38
Study: 18499602

Group type: EXPERIMENTAL
Intervention: Passiflora incarnata (500 mg, Passipy IranDarouk)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16595611

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg kg(‐1) over 10 min; followed by 0.1‐0.7 microg kg(‐1) h(‐1) i.v. infusion (Group D)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Midazolam 20 microg kg(‐1) i.v.; followed by 0.5 mg i.v. boluses as required (Group M)
Number of subjects: 44
Study: 12700794

Group type: EXPERIMENTAL
Intervention: Folic acid (250 micro;g) + Iron (120 mg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Folic acid (250 micro;g) + Iron (80 mg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Folic acid (250 micro;g) + Zinc sulfate + Iron (120 mg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Folic acid (250 micro;g) + Zinc sulfate + Iron (80 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Iron (120 mg) only (routine dosage)
Number of subjects: 74
Study: 10993035

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patch (Climara) applied on buttocks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transdermal estradiol patch (Climara) applied on abdomen
Number of subjects: 0
Study: 9140141

Group type: EXPERIMENTAL
Intervention: Oral vanadyl sulphate (0.5 mg/kg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8101532

Group type: COMPARATOR
Intervention: Neurohumoral activation measured by plasma neurohormones
Number of subjects: 519
Study: 3470356

Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection using pistol-pressure syringe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection using standard-grip syringe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of syringe and solution injected
Number of subjects: 0
Study: 30066759

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (0.015%) applied on face/scalp for 3 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (0.05%) applied on forearm for 2 days
Number of subjects: 27
Study: 27034455

Group type: EXPERIMENTAL
Intervention: Automated interactive voice response tool providing real-time patient-reported data, with three brief interactive calls every 2 months after medication prescription.
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Non-interactive automated educational phone calls.
Number of subjects: 1206
Study: 25154739

Group type: EXPERIMENTAL
Intervention: Combination therapy (SeR-Se-Ly + tamsulosin 0.4 mg)
Number of subjects: 225
Study: 24192015

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 21166767

Group type: EXPERIMENTAL
Intervention: Acupuncture (Sanyinjiao, SP6)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Unrelated acupoint (Xuanzhong, GB39)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Nonacupoint
Number of subjects: 194

Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 194
Study: 18853232

Group type: EXPERIMENTAL
Intervention: Wholemeal wheat bread (WB) (133 g)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Glucose (55 g) in water
Number of subjects: 4
Study: 17145606

Group type: EXPERIMENTAL
Intervention: Hydroxyurea capsules
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydroxyurea tablets
Number of subjects: 26
Study: 14524645

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent SSRI therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0
Study: 10921274

Group type: EXPERIMENTAL
Intervention: Forlax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forlax with prokinetics
Number of subjects: 0
Study: 8922787

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg daily)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Amphotericin B (25-50 mg daily; 0.67 mg/kg daily for neutropenic patients)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 164
Study: 1551115

Group type: EXPERIMENTAL
Intervention: Thioether-lipid conjugate of ara-C (ara-CDP-DL-PTBA) at 250 mg/kg/week for 3 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline vehicle (control)
Number of subjects: 7
Study: 6364882

Group type: EXPERIMENTAL
Intervention: Oral trimeprazine plus droperidol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral trimeprazine
Number of subjects: 60
Study: 31221697

Group type: EXPERIMENTAL
Intervention: GLP-1Ra treatment for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Obese subjects with diabetes
Number of subjects: 20
Study: 30627180

Group type: EXPERIMENTAL
Intervention: Budesonide nebulizer suspension (Pulmicort Nebulizer)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Budesonide inhalation suspension (Pulmicort Turbuhaler)
Number of subjects: 90
Study: 27632179

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg daily oral administration, n = 209)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo (n = 214)
Number of subjects: 423
Study: 25379852

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery with prolonged time to surgery (TTS)
Number of subjects: 325
Study: 23404424

Group type: EXPERIMENTAL
Intervention: 2% tetracaine
Number of subjects: 99

Group type: COMPARATOR
Intervention: 4% lidocaine
Number of subjects: 99
Study: 20441775

Group type: EXPERIMENTAL
Intervention: Young adults (21-26 years)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Middle-aged adults (50-55 years)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Older adults (70-77 years)
Number of subjects: 42
Study: 18469574

Group type: EXPERIMENTAL
Intervention: Treadmill training for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonintervention group (Control)
Number of subjects: 30
Study: 16435692

Group type: EXPERIMENTAL
Intervention: Continuous matching task at low difficulty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous matching task at moderate difficulty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous matching task at high difficulty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NASA‐Task Load Index rating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG signals analysis using wavelet transform
Number of subjects: 0
Study: 12738624

Group type: EXPERIMENTAL
Intervention: BNP (4 pmol. kg‐1. min‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10229249

Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injections (ISW)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard care (back massage, whirlpool bath, and liberal mobilization)
Number of subjects: 34
Study: 7890212

Group type: EXPERIMENTAL
Intervention: Gorging pattern (two meals daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nibbling pattern (four to seven meals daily)
Number of subjects: 8
Study: 1979541

Group type: EXPERIMENTAL
Intervention: Acrivastine administered 30, 45, 60 or 90 min before challenge
Number of subjects: 0
Study: 213092

Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: tubocurarine
Number of subjects: 21

Group type: COMPARATOR
Intervention: no block
Number of subjects: 21
Study: 30415988

Group type: EXPERIMENTAL
Intervention: Adjuvant modified FOLFIRINOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 180 mg/m2, and 5‐FU 2.4 g/m2 over 46 hours) every 2 weeks for 24 weeks (12 cycles)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5‐FU bolus 400 mg/m2, then 2.4 g/m2 over 46 hours) every 2 weeks for 24 weeks (12 cycles)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Adjuvant modified FOLFIRINOX
Number of subjects: 640

Group type: COMPARATOR
Intervention: Modified FOLFOX6
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 640
Study: 28647848

Group type: EXPERIMENTAL
Intervention: Slit incision of the RWM (70 cases)
Number of subjects: 118

Group type: COMPARATOR
Intervention: RWM cruciate incision (48 cases)
Number of subjects: 118
Study: 25384542

Group type: EXPERIMENTAL
Intervention: Bifocal treatment of myopia
Number of subjects: 240
Study: 23473984

Group type: EXPERIMENTAL
Intervention: Buttonhole cannulation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual-practice cannulation
Number of subjects: 140
Study: 21777701

Group type: EXPERIMENTAL
Intervention: Parent-mediated approach utilizing physician's brief motivational interviewing and parent group sessions
Number of subjects: 0
Study: 19002369

Group type: EXPERIMENTAL
Intervention: 800 mg oral clodronate (Bonefos) daily over 3 years
Number of subjects: 3974
Study: 16538112

Group type: EXPERIMENTAL
Intervention: Biliary stenting alone (7 Fr stent)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Biliary stenting plus sphincterotomy (10 Fr stent)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (biliary stenting alone and biliary stenting plus sphincterotomy)
Number of subjects: 52
Study: 15513572

Group type: EXPERIMENTAL
Intervention: Combined growth hormone (GH) and GnRH analogue treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: GnRH analogue treatment alone
Number of subjects: 46
Study: 10654946

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (pulse oximetry targeted at 96% to 99%)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Conventional oxygen (pulse oximetry targeted at 89% to 94%)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 649

Group type: COMPARATOR
Intervention: Conventional oxygen
Number of subjects: 649
Study: 9295978

Group type: EXPERIMENTAL
Intervention: Endoscopy at the end of initial treatment (group 1)
Number of subjects: 369

Group type: COMPARATOR
Intervention: No endoscopy at the end of initial treatment (group 2)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Endoscopy at 6 months (group 1)
Number of subjects: 369

Group type: COMPARATOR
Intervention: No endoscopy at 6 months (group 2)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Pharmacy costs (group 1)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Pharmacy costs (group 2)
Number of subjects: 369
Study: 8342092

Group type: EXPERIMENTAL
Intervention: INTERCEED Barrier
Number of subjects: 134

Group type: COMPARATOR
Intervention: Microsurgery alone
Number of subjects: 134
Study: 3537216

Group type: EXPERIMENTAL
Intervention: 5-day pulse chemotherapy every 3 weeks (group I)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Continuous chemotherapy (group C)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Semi-continuous chemotherapy (group G)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: 3 years of chemotherapy
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Alterations in fractionation of cranial irradiation
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Initial leucocyte count
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Gender (girls)
Number of subjects: 496
Study: 30643052

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study: 27564126

Group type: EXPERIMENTAL
Intervention: Early class III protraction facemask treatment (PFG)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control/no treatment (CG)
Number of subjects: 73
Study: 24995559

Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs‐enriched diet
Number of subjects: 0
Study: 22920811

Group type: EXPERIMENTAL
Intervention: Cybercycle exergame
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard stationary bicycle
Number of subjects: 20
Study: 20181868

Group type: EXPERIMENTAL
Intervention: Fe-deficient group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fe-adequate group
Number of subjects: 0
Study: 18937608

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol bolus of 0.25 mg kg(‐1); no lockout interval; n = 50
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anesthesiologist-controlled sedation (ACS) with continuous infusion of propofol 1% (3 mg kg(‐1) h(‐1); n = 50)
Number of subjects: 100
Study: 16235978

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12427411

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 10707137

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fortified tobramycin (1.5%) and cefazolin (10%) solutions (control group)
Number of subjects: 30
Study: 8550186

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (MAb) 61BG 1.3, 3 micrograms per tooth, applied at 1, 3, 7, and 10 days after suppression of P. gingivalis.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control group), applied at 1, 3, 7, and 10 days after suppression of P. gingivalis.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (MAb) 61BG 1.3
Number of subjects: 14
Study: 1841774

Group type: EXPERIMENTAL
Intervention: High-dose verapamil treatment (Isoptin RR, 240 mg verapamil, twice daily)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 196

Group type: COMPARATOR
Intervention: Different dosages of diltiazem
Number of subjects: 196
Study: 6138074

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vesparax (barbiturate combination)
Number of subjects: 0
Study: 31172446

Group type: EXPERIMENTAL
Intervention: GDC-0276 single doses (SD) of 2–270 mg (PIC) and 45–540 mg (CD)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: GDC-0276 multiple doses (MD) of 15–540 mg divided into two or three doses/day
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 183
Study: 26879545

Group type: EXPERIMENTAL
Intervention: Intraperitoneal paclitaxel (PTX) at 60 mg/m2 on the day of surgery and on days 14, 21, 28, 42, 49, and 56
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intravenous paclitaxel (PTX) at 80 mg/m2 on the same schedule
Number of subjects: 83
Study: 25703611

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy for PTSD
Number of subjects: 116
Study: 22928878

Group type: EXPERIMENTAL
Intervention: Tactile display applied to the forearm skin transferring tactile input from an artificial hand.
Number of subjects: 10
Study: 21913487

Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Mecillinam
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate
Number of subjects: 212
Study: 19853700

Group type: EXPERIMENTAL
Intervention: Rhythm control strategy
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Postoperative rhythm control
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Mortality or stroke at 30 days
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Mortality at 3 years
Number of subjects: 2794
Study: 15572876

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 12791225

Group type: EXPERIMENTAL
Intervention: Topical ophthalmic NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 0
Study: 10203909

Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip with scaling and root planing (SRP)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo chip with scaling and root planing (SRP)
Number of subjects: 565
Study: 8915645

Group type: EXPERIMENTAL
Intervention: ADCON-L Anti-Adhesion Barrier Gel
Number of subjects: 0
Study: 1871184

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) supplementation (45 mg GLA and 360 mg linoleic acid, 2 capsules daily for 4 months, then 4 capsules daily for 4 months)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 11
Study: 6137500

Group type: COMPARATOR
Intervention: Prazosin (4 mg, 2 pills of Minipress Pfizer per day) for 7 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31425171

Group type: EXPERIMENTAL
Intervention: Pharmacist-led hypertension management program with barbers promoting follow-up and pharmacists prescribing antihypertensive therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 28194611

Group type: EXPERIMENTAL
Intervention: 3D echocardiography-guided LV lead placement
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CRT insertion
Number of subjects: 47
Study: 27779354

Group type: EXPERIMENTAL
Intervention: Parecoxib 0.25 mg·kg‐1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Parecoxib 1 mg·kg‐1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Parecoxib 2 mg·kg‐1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Parecoxib (various doses)
Number of subjects: 59
Study: 24314863

Group type: EXPERIMENTAL
Intervention: Whey protein (10 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey protein (20 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose (10 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose (20 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study: 23018869

Group type: EXPERIMENTAL
Intervention: 4-week sensory relearning home program
Number of subjects: 31

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 31
Study: 19445432

Group type: EXPERIMENTAL
Intervention: Strength training (n = 81)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard care (n = 82)
Number of subjects: 163
Study: 17994473

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (4, 20, 40, and 60 mg) during aripiprazole maintenance
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo during aripiprazole maintenance
Number of subjects: 8
Study: 16400891

Group type: EXPERIMENTAL
Intervention: Epinephrine (2, 4, and 8 actuations administered at 17‐minute intervals)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Albuterol (6 cumulative actuations administered at 17‐minute intervals)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 8
Study: 11952198

Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management (CM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study: 9797799

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8573426

Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg/day for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etidronate 400 mg/day
Number of subjects: 0
Study: 2229455

Group type: EXPERIMENTAL
Intervention: 100 mg velnacrine tid for 28 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: 25 mg velnacrine bid
Number of subjects: 56

Group type: COMPARATOR
Intervention: 50 mg velnacrine bid
Number of subjects: 56

Group type: COMPARATOR
Intervention: 100 mg velnacrine bid
Number of subjects: 56
Study: 322533

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229